SynthesisJournal of the National Cancer Institute2023

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials.

Yuanfang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.